COVID vaccination improves effectiveness of cancer treatment

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Covid-19 could reduce the success of cancer treatment or cause severe side effects. A recent study by the Universities of Bonn and Shanxi in the People's Republic of China now gives the all-clear in this regard. According to the study, the cancer drugs actually worked better after vaccination with the Chinese vaccine SinoVac than in unvaccinated patients. The results are published as a "Letter to the editor" in the journal Annals of Oncology, but are already available online.

Many cancer cells are capable of subverting the body's immune response. They do this by pushing a kind of button on the immune cells, the PD-1 receptor. In this way, they effectively shut down these endogenous defense forces. Drugs can be used to block PD-1 receptors. This enables the immune system to fight the tumor more effectively.

Vaccination against Covid also stimulates the immune response, involving the PD-1 receptor. "It was feared that the vaccine would not be compatible with anti-PD-1 therapy," explains Dr. Jian Li of the Institute of Molecular Medicine and Experimental Immunology (IMMEI) at the University Hospital Bonn. "This risk is especially true for nasopharyngeal cancer, which, like the SARS Cov-2 virus, affects the upper respiratory tract."

Together with cooperation partners from the People's Republic of China, the bioinformatician has now investigated whether this concern is justified. More than 1,500 patients treated in 23 hospitals from all over China participated in the analysis. Such multi-center studies are considered to be particularly informative because the participants are very diverse and, moreover, the results are not distorted by regional characteristics.

Vaccinated patients responded better to cancer therapy

A subset of 373 affected individuals had been vaccinated with the Chinese Covid vaccine SinoVac. "Surprisingly, they responded significantly better to anti-PD-1 therapy than the unvaccinated patients," explains Prof. Dr. Christian Kurts, Director of IMMEI and member of the Transdisciplinary Research Area "Life & Health" and the Cluster of Excellence ImmunoSensation. "Furthermore, they did not experience severe side effects more often." The researchers cannot say why the treatment was more successful after vaccination. "We assume that vaccination activates certain immune cells, which then attack the tumor," says Prof. Dr. Qi Mei of Shanxi University Hospital. "We will now investigate this hypothesis further."

Nasopharyngeal cancer is quite rare in this country. In southern China and other countries in Southeast Asia, however, the disease is widespread. One of the suspected reasons for this is the frequent use of air conditioning in the hot and humid regions. Nutritional factors also appear to play an important role. In Taiwan, nasopharyngeal cancer is now considered one of the leading causes of death among young men.

Hua YJ, Liu YL, Wen K, Kurts C, Wu H, Mei Q, Li J.
Potentially Improved Response of COVID-19 vaccinated Nasopharyngeal Cancer Patients to Combination Therapy with Anti-PD-1 Blockade and Chemotherapy.
Annals of Oncology, 2022. doi: 10.1016/j.annonc.2022.10.002

Most Popular Now

Pfizer completes acquisition of Global Blood Thera…

Pfizer Inc. (NYSE: PFE) announced the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, deve...

GSK announces expanded collaboration with Tempus i…

GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus...

Bayer signs grant agreement to advance innovation …

Bayer announced that it has received a grant from the Bill & Melinda Gates Foundation. As part of the grant, Bayer and the Bill & Melinda Gates Foundation have each commi...

UCLA researchers identify a gene as a potential ta…

Research led by doctors and scientists at UCLA Jonsson Comprehensive Cancer Center and the UCLA Jane & Terry Semel Institute for Neuroscience & Human Behavior have identi...

Why late-night eating leads to weight gain, diabet…

Northwestern Medicine scientists have uncovered the mechanism behind why eating late at night is linked to weight gain and diabetes. The connection between eating time...

Novel derivative of "love hormone" oxyto…

The cognitive decline and memory loss observed in Alzheimer's disease (AD) is attributed to the accumulation of β-amyloid protein (Aβ), which impairs neural function in t...

Pfizer and BioNTech announce positive early data f…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunog...

Protein IDs, drug candidates, show promise for COV…

A highly innovative method using the latest technology has generated a comprehensive list of SARS-CoV-2 viral and human proteins that interact with each other, with one s...

Fighting tumors with magnetic bacteria

Scientists around the world are researching how anti-cancer drugs can most efficiently reach the tumours they target. One possibility is to use modified bacteria as "ferr...

Possible target for treating and preventing osteoa…

Wear and tear on joints can lead to inflammation, breakdown of cartilage and development of osteoarthritis. Scientists at UF Scripps Biomedical Research have found a poss...

Experimental cancer drug could be effective in tre…

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF). Saracatinib worked as well or better than two...

Making pharmacy more sustainable

In the article published in the prestigious scientific journal Science, a group of international researchers, including Gorka Orive, Doctor of Pharmacy and researcher in ...